Buyru Nur, Altinisik Julide, Gurel Cigdem Bayram, Ulutin Turgut
Cerrahpasa Medical Faculty, Department of Medical Biology, Istanbul University, Istanbul, Turkey.
Clin Appl Thromb Hemost. 2003 Oct;9(4):333-6. doi: 10.1177/107602960300900409.
PAI-2 is one of the regulators of the fibrinolytic system. The importance of the fibrinolytic cascades in the pathogenesis of myocardial infarction has been demonstrated by many investigators. Recently, some investigators have shown that two variants of PAI-2, designated A and B, are associated with the formation of large molecular PAI-2 complexes. This polymorphism is therefore present a genetic predisposition for the development of coronary artery disease and multiple sclerosis. Therefore, the prevalence of this polymorphism among 45 patients with MI and 20 control subjects was investigated. The AA genotype of the PAI-2 gene was found to be more frequent among those subjects with MI. These data provide evidence that a polymorphism of the PAI-2 gene is associated with an increased risk of MI.
纤溶酶原激活物抑制剂-2(PAI-2)是纤维蛋白溶解系统的调节因子之一。许多研究人员已证明纤维蛋白溶解级联反应在心肌梗死发病机制中的重要性。最近,一些研究人员表明,PAI-2的两种变体,即A和B,与大分子PAI-2复合物的形成有关。因此,这种多态性是冠状动脉疾病和多发性硬化症发展的遗传易感性因素。因此,对45例心肌梗死患者和20例对照受试者中这种多态性的患病率进行了调查。发现PAI-2基因的AA基因型在心肌梗死患者中更为常见。这些数据证明PAI-2基因的多态性与心肌梗死风险增加有关。